Newswise — HOUSTON ― The University of Texas MD Anderson Cancer Center and RaySearch Laboratories today announced a strategic alliance with the aim of enhancing cancer radiation therapy through several initiatives, including more precisely targeting of tumors, and improving upon, and making more available, an existing radiation therapy called adaptive radiation therapy (ART), which is currently only used at highly specialized care centers.
Successful radiation therapy depends on the ability to delineate the precise tumor location. Since most radiation treatments are delivered over several weeks, a number of variables can compromise treatment accuracy. Traditionally, additional margins are set around the target area to allow for tumor movement and variations in how patients are positioned during treatment.
However, these margins do not always compensate for unexpected changes in the tumor and surrounding normal tissue over the full course of radiation treatment. ART uses frequent imaging to give an up-to-date assessment of physical changes and enable precisely tailored treatment for each patient.
The alliance builds upon a previously established relationship between RaySearch and MD Anderson centered on RayCare®, RaySearch’s new oncology information system. This new collaboration combines MD Anderson’s clinical data and expertise with the latest technology and platforms available through RaySearch and will focus on the following areas:
- Integration of advanced imaging into the treatment planning process to help define the tumor targets better.
- Management of changes in the tumor that may occur during treatment, and monitoring and adjusting treatment to accommodate each patient’s individual circumstances at any point during therapy.
- Building software components with the aim of creating a new standard of care in radiation therapy.
“The technology to perform ART has been around for a number of years and studies have demonstrated its advantages,” said Caroline Chung, M.D., assistant professor of Radiation Oncology at MD Anderson. “However, it is a complex process that has not yet been broadly adopted in clinical practice and is largely limited to highly specialized care centers. The goal of this collaboration is to establish a methodology and workflow, clinically tested at MD Anderson, which can be streamlined and automated to enable adaptive radiation therapy on a larger scale.”
The combination of advanced imaging data, with platforms such as RayCare and the treatment planning system RayStation®, will be vital to improving the delineation of tumors. Together, they provide a novel opportunity for more personalized treatment. The development of digital workflows has the potential to improve patient care at MD Anderson and other cancer care facilities.
“This strategic alliance between MD Anderson and RaySearch is a very significant milestone for RaySearch,” said Johan Löf, Ph.D., CEO and founder of RaySearch. “It is one of the most ambitious collaborations that we have ever engaged in. With RayStation and RayCare as the technological platforms, paired with the expertise of MD Anderson, I believe that we can make tremendous progress toward our vision of a world where cancer is conquered.”
RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation treatment planning system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. The company recently launched the next-generation oncology information system, RayCare*, which comprises a new product area for RaySearch. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003. To learn more about RaySearch, go to: www.raysearchlabs.com
* Subject to regulatory clearance in some markets.
- 30 -